SHANNON BUSTER: Open Payments
NPI 1558601450 · PAPILLION, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,695 in 99 payments from 23 companies in 2025. Trend: 2023 $1,701 · 2024 $1,690 · 2025 $1,695
Food & beverage: $1,695
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $502 |
| AstraZeneca Pharmaceuticals LP | 7 | $189 |
| Otsuka America Pharmaceutical, Inc. | 8 | $142 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| Lilly USA, LLC | 4 | $88 |
| Lundbeck LLC | 4 | $80 |
| PFIZER INC. | 5 | $78 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Astellas Pharma US Inc | 3 | $75 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
Products named: VRAYLAR, REXULTI, QULIPTA, UBRELVY, CAPLYTA, NURTEC ODT, Auvelity, Veozah.
Industry payments across NE — which companies pay providers there.
